诺华与中国的艾博生物达成了一项价值最高达78亿美元的合作协议，将引进一款候选药物并获得后续疗法的开发权。这是西方大型制药企业与中国新兴生物科技公司之间的最新合作案例。
Novartis NOVN -0.22%decrease; down pointing triangle struck a deal valued at up to $7.8 billion to license a drug candidate from China’s Abogen Biosciences and gain options over future therapies, the latest tie-up between a big Western drugmaker and a Chinese upstart.
据艾博生物周五透露，这家瑞士制药企业将支付5.75亿美元作为首付款；若所有开发选项均被行使，还将支付最高达72亿美元的后续款项。
The Swiss drugmaker is paying $575 million upfront and could make additional payments of up to $7.2 billion if options on all programs are exercised, Abogen said Friday.